Drugs / FDOPA
FDOPA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02176720 | May 2014 → Mar 2016 | glioblastoma | The Methodist Hospital Research Institute | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00674440 | Dec 2004 → Dec 2008 | congenital isolated hyperinsulinism | Children's Hospital of Philadelphia | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FDOPA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02176720 ↗ |
| Known as | 18F-fluoro-L-dihydroxyphenylalanine | “OBJECTIVES: To assess the accuracy of 18F-fluoro-L-dihydroxyphenylalanine ([18F]-DOPA) PET scans to diagnose focal versus diffuse disease and to localize focal lesions in...” PMID 17236890 ↗ Feb 2007 |
| Known as | [18F]-DOPA | “OBJECTIVES: To assess the accuracy of 18F-fluoro-L-dihydroxyphenylalanine ([18F]-DOPA) PET scans to diagnose focal versus diffuse disease and to localize focal lesions in...” PMID 17236890 ↗ Feb 2007 |
| Modality | Diagnostic / imaging agent | “F-DOPA can also be used for positron emission tomography (or PET), an imaging technique used in nuclear medicine departments.” NCT00674440 ↗ |
| Route | Intravenous | “Patients were injected intravenously with [18F]-DOPA” PMID 17236890 ↗ Feb 2007 |